FUTURE OF INSULIN GLARGINE BIOSIMILARS IN 2024

Insulin glargine, a long-acting insulin analog, is essential in diabetes management, providing reliable glucose control for up to 24 hours. As diabetes rates continue to rise globally, biosimilars of insulin glargine offer a more affordable alternative to branded treatments like Sanofi's Lantus, helping to reduce the financial burden on patients an